The very low density (VLDL) apolipoproteins of 12 male patients with gout have been studied by analytical isoelectric focusing. The relative percentage distribution of the C apolipoproteins was calculated and compared with that from 12 normolipidaemic and 12 'lipid-matched' controls.
Many studies have shown a high incidence of hyperlipidaemia in patients with gout, commonly hypertnxglyceridaemia due to raised endogenous VLDL. -3 As well as lipid, VLDL particles contain B, C, and E apoproteins, and recent discoveries about the function of these have had considerable impact on the understanding of disorders of lipid metabolism. Lipoprotein lipase (LPL) catalyses the conversion of VLDL to LDL at capillary endothelial sites.4 5 Apo CII is an activator6 of LPL, and apo CIII has been reported to inhibit this enzyme in vitro.7
To date, studies of hypertriglyceridaemia in gout have concentrated on the lipid moiety. The purpose of this study was to look for an abnormality in the C apoprotein component of VLDL in men with gout, which might explain their predisposition to hypertriglyceridaemia.
SUBJECTS
Twelve men with gout (mean age of 48 years) were selected at random from the rheumatology clinic. They all gave informed consent to the study which had been approved by the local ethical committee. All their drug treatment was stopped for a period of six weeks, and they were also requested to reduce their alcohol intake as much as possible and avoid self medication. At Gel preparation Polyacrylamide gels were prepared by mixing the following solutions: 2-4 ml of 13-75% acrylamide w/v-0*8% N,N-methylene bis(acrylamide) w/v in 8 M urea; 7 5 ml 8 M urea; 1-2 ml glycerol; 0-5 ml N,N,N'N'-tetramethylethylenediamine; and 0-6 ml ampholine pH 4-6 (LKB Produckter). Chemical polymerisation was carried out by adding 0 The stained gels were scanned at 560 nm in a Pye Unicam (SP800) spectrophotometer fitted with a gel scanning attachment. The peak area (heightxwidth at ½/2 peak height) was calculated for each apo C band, and the contribution of each individual band was expressed as a percentage of the total area of quantified apo C. The within-assay coefficient of variation was 2%, and between-assay coefficient of variation ranged from 2-7 to 7%.
Previous work in this department'3 has established that this method of quantification is valid. The absorption of the bands produced by the C apoproteins is linear over a wide ran e. This has also been confirmed by other workers.
STATISTICAL ANALYSIS
The differences observed in the distribution of C apoproteins in the three groups were tested for statistical significance by Wilcoxon's rank sum test for unpaired data.
Results
Relevant clinical findings in the gout patients are shown in Table 1 and their serum and VLDL cholesterol and triglyceride levels in Table 2 . The serum and VLDL cholesterol and triglyceride level of the lipid-matched controls are shown in Table 3 .
Seven of the 12 gout patients (58%) had a hyperlipidaemia: five type IV and two type lIb.
group Three patients with hyperlipidaemia and one with normal serum lipids were obese. The correlation between hypertriglyceridaemia and alcohol consumption was not absolute: one patient who was a non-drinker had type IV. The relative distribution of the C apoproteins is given in Table 4 . The gout patients had a lower mean CII and a higher mean C1112 than the normolipidaemic controls and a lower mean CII than the lipid-matched controls. The ratio CII/CIII2 was lower in the gout patients than in both control groups. These differences were all statistically significant.
Analysis of the apo C distribution in the gout patients by lipid status (Table 5) showed that the low CII/C1112 ratio was not just confined to those with type IV hypertriglyceridaemia but was also present in those with type II hyperlipidaemia and in subjects with normal lipid levels. 
Discussion
The results of this study suggest a mechanism which may predispose patients with gout to hypertriglyceridaemia. Apo CII activates the breakdown of triglyceride by lipoprotein lipase (LPL),2 and apo CIII appears to have an inhibitory effect on this process, at least in vitro.7 Apo CII attaches to LPL at capillary endothelium and facilitates penetration of the enzyme into the lipid core of VLDL.15 It is not certain how apo CIII opposes this process, but it is known that the addition of CIII protein to triglyceride emulsions has a pronounced inhibitory effect on hepatic removal.'6 The degree of sialylation of glycoproteins such as apo CIII may affect this inhibitory potential,'7 and it could be relevant that apo C1112 contains 2 mol/mol sialic acid whereas apo CIII, and CIII contain 1 and 0 mol/mol respectively.'2 Thus an alteration in the ratio of CII/CIII2 could render the VLDL relatively resistant to the action of LPL. It is of interest that in the present study the abnormality was also found in the normolipidaemic gout patients. This suggests that the gouty diathesis itself is associated with an abnormal distribution of VLDL apo C which does not necessarily show itself in hypertriglyceridaemia.
A deficiency of apolipoprotein CII has been discussed in a kindred with severe hypertriglyceridaemia.21 22 Homozygotes with this condition have marked hypertriglyceridaemia, but heterozygotes with only 50% or normal levels of apo CII do not have raised levels of triglycerides. Thus it appears that in this kindred, with its particular environment and possible low fat intake,2 apo CII levels of half those in a control preparation are sufficient to keep serum triglycerides within the normal range. Thus a decrease in ratio of apo CII to apo CII12, as in our gout patients (0-59 compared with 0-96 and 1-09 in normolipidaemic and hyperlipidaemic controls respectively), may predispose to hypertriglyceridaemia. This has also been suggested by the studies of Kashyap et al. '4 We do not have any data from this study that help to clarify the cause of the apo C abnormality. VLDL is assembled and secreted by the liver without apo C, which is ac uired later from high density lipoproteins (HDL). As triglyceride-rich VLDL is transformed' into cholesterol-rich LDL by LPL, apo C transfers back to HDL.19 Hyperuricaemia itself could possibly interfere with the recirculation of the apo C proteins, but many patients with hyperuricaemia do not have hypertriglyceridaemia. Conversely many people with raised uric acid levels do not have gout. It has been suggested that an additional factor may be required to facilitate nucleation of the solute into crystal, and an abnormality of proteoglycans has been proposed as the predisposing factor.20 In this regard it may be relevant that the LPL is attached to capillary endothelial cells via the proteoglycan heparan sulphate,18 and an alteration here could affect the rate and efficiency of apo C-mediated VLDL on metabolism. Such a hypothesis would be in favour of the concept of a gouty diathesis and provide an explanation for the high incidence of hypertriglyceridaemia in gout. Studies on the release of LPL following heparin in patients with gout may help to clarify this. 
